BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 6, 2026
Home » Authors » Anette Breindl

Anette Breindl

Articles

ARTICLES

Best-laid plans of mice and men derailed by pigs

Nov. 17, 2017
By Anette Breindl

Best-laid plans of mice and men derailed by pigs

Nov. 16, 2017
By Anette Breindl
Therapeutic administration of interleukin-10 (IL-10) into the cerebrospinal fluid through intrathecal gene therapy caused fatal meningitis in swine, an unexpected toxicity that had not been seen in multiple rodent experiments.
Read More

A TALE of gene editing methods

Nov. 16, 2017
By Anette Breindl
As far as gene editing technologies go, clustered regularly interspaced short palindromic repeats, or CRISPR, tends to suck up all the oxygen in the room.
Read More

Cradle to grave, small changes in protein levels make big difference

Nov. 15, 2017
By Anette Breindl
WASHINGTON – "There is nothing more beautiful than 20/20 hindsight," Huda Zoghbi told the audience at the 2017 Annual Meeting of the Society for Neuroscience.
Read More

Good models, good questions make for translatability

Nov. 14, 2017
By Anette Breindl
WASHINGTON – "In the 21st century, there is not a single cure for a single neurodegenerative disease. Not one. . . . There are no therapeutics. There is no strategy. There is bupkes in the 21st century."
Read More

Bench Press: BioWorld looks at translational medicine

Nov. 13, 2017
By Anette Breindl
Fibroblasts are the major cell type that is responsible for wound healing, as they migrate to the sites of injuries and secrete extracellular matrix molecules that physically allow repair of damaged tissue.
Read More

Focusing downstream may help untangle AD target woes

Nov. 10, 2017
By Anette Breindl

Transgenic stem cells replace almost total organ

Nov. 9, 2017
By Anette Breindl
Transgenic skin stem cells combined with improved tissue engineering methods have enabled an almost total autologous skin transplant for a 7-year-old child with junctional epidermolysis bullosa (JEB), a rare genetic disease that causes the top layer of skin, the epidermis, to separate from the underlying dermis.
Read More

Focusing downstream may help untangle AD target woes

Nov. 8, 2017
By Anette Breindl
Treating aging rats with an experimental compound that prevented neuronal cell death protected the animals from both depressive symptoms that are often the first symptom of Alzheimer’s disease (AD), and the memory decline that follows. The compound did not, however, affect the amyloid beta (a-beta) plaques, tau phosphorylation and inflammation that are widely considered to be the toxic agents behind neuronal demise in AD.
Read More

Microbiome's influence on checkpoint blockade is confirmed in clinic

Nov. 6, 2017
By Anette Breindl
View All Articles by Anette Breindl

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 5, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Auvelity

    Axsome’s Auvelity cleared for large Alzheimer’s agitation market

    BioWorld
    Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing